V
Viyyoor M. Girijavallabhan
Researcher at Schering-Plough
Publications - 223
Citations - 5010
Viyyoor M. Girijavallabhan is an academic researcher from Schering-Plough. The author has contributed to research in topics: NS3 & Farnesyl Protein Transferase. The author has an hindex of 36, co-authored 223 publications receiving 4894 citations. Previous affiliations of Viyyoor M. Girijavallabhan include Duke University.
Papers
More filters
Journal Article
Antitumor Activity of SCH 66336, an Orally Bioavailable Tricyclic Inhibitor of Farnesyl Protein Transferase, in Human Tumor Xenograft Models and Wap-ras Transgenic Mice
Ming Liu,Matthew S. Bryant,Jianping Chen,Suining Lee,Bohdan Yaremko,Phil Lipari,Michael Malkowski,Eric Ferrari,Loretta L. Nielsen,Nicholas Prioli,Janet Dell,Dineshwar Sinha,Jameel Syed,Walter A. Korfmacher,Amin A. Nomeir,C-C. Lin,Lynn Wang,Taveras Arthur G,Doll Ronald J,Njoroge F George,Alan K. Mallams,Stacy W. Remiszewski,Joseph J. Catino,Viyyoor M. Girijavallabhan,Paul Kirschmeier,W. Robert Bishop +25 more
TL;DR: Sch 66336 as mentioned in this paper is a small molecule farnesyl protein transferase inhibitor that shares a common tricyclic nucleus and compete with peptide/protein substrates for binding to the Farnesyl Protein Transferase.
Patent
Peptides as ns3-serine protease inhibitors of hepatitis c virus
Anil K. Saksena,Viyyoor M. Girijavallabhan,Raymond G. Lovey,Edwin Jao,Frank Bennett,Mccormick Jinping,Haiyan Wang,Russell E. Pike,Stephane L. Bogen,Yi-Tsung Liu,Ashok Arasappan,Parekh Tejal N,Pinto Patrick A,F. George Njoroge,Ashit K. Ganguly,Terence K. Brunck,Scott Jeffrey Kemp,Levy Odile Esther,Lim-Wilby Marguerita +18 more
TL;DR: In this paper, the authors present novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds and methods of using them to treat disorders associated with the HPCP protease.
Patent
Pharmaceutically active compounds
TL;DR: In this article, the authors describe compounds of the formula "STR1" wherein Z, X, Q, Y, W, and W' are described as described in this paper, and some of these compounds have antiinflammatory activity and are PAF inhibitors.
Journal ArticleDOI
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection
Srikanth Venkatraman,Stephane L. Bogen,Ashok Arasappan,Frank Bennett,Kevin X. Chen,Edwin Jao,Yi-Tsung Liu,Raymond G. Lovey,Hendrata Siska,Yuhua Huang,Weidong Pan,Parekh Tejal N,Patrick Pinto,Veljko Popov,Pike Russell E,Sumei Ruan,Santhanam Bama,Bancha Vibulbhan,Wanli Wu,Weiying Yang,Jianshe Kong,Xiang Liang,Jesse Wong,Rong Liu,Nancy Butkiewicz,Robert Chase,Andrea Hart,Sony Agrawal,Paul Ingravallo,John Pichardo,Rong Kong,Bahige M. Baroudy,Bruce A. Malcolm,Zhuyan Guo,Andrew Prongay,Vincent Madison,Lisa Broske,Xiaoming Cui,Kuo-Chi Cheng,Yunsheng Hsieh,Jean-Marc Brisson,Danial Prelusky,Walter A. Korfmacher,Ronald E. White,Susan Bogdanowich-Knipp,Pavlovsky Anastasia,Prudence Bradley,Anil K. Saksena,Ashit K. Ganguly,Piwinski John J,Viyyoor M. Girijavallabhan,F. George Njoroge +51 more
TL;DR: The SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described.
Patent
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
Timothy J. Guzi,Kamil Paruch,Michael P. Dwyer,Doll Ronald J,Viyyoor M. Girijavallabhan,Dillard Lawrence W,Vinh D. Tran,Zhen Min He,Ray Anthony James,Haengsoon Park +9 more
TL;DR: In this paper, a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds and methods of treatment, prevention, inhibition, or amelioration of diseases associated with the CDKs using such compounds or pharmaceutical compositions are described.